Cyprumed GmbH and Merck & Co., Inc. have entered a Non-Exclusive License and Option Agreement to develop oral formulations of peptides using Cyprumed’s drug delivery technology.
MSD gains global non-exclusive rights and options for exclusive licenses on specific targets. Cyprumed may receive up to $493 million in various milestone payments, with potential for more if MSD exercises exclusive options. MSD will handle the development and commercialization of any resulting products.
Both companies expressed enthusiasm, highlighting the collaboration as a validation of Cyprumed’s technology and it’s importance and a boost for MSD’s peptide pipeline.
This is a summary of an article published by Cyprumed. The full version of the article is available here.
